Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)

被引：0
|
作者：
Bell, Jill A. [1 ]
Cherepanov, Dasha [1 ]
Revicki, Dennis [2 ]
Speck, Rebecca M. [2 ]
Swett, Laura [2 ]
Stumpo, Kate [1 ]
Rong, Yuanxin [1 ]
Gordon, Leo I. [3 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Evidera PPD, Bethesda, MD USA
[3] Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
QUALITY OF LIFE RESEARCH | 2019年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
B204.2
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [41] Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.
    Davids, Matthew Steven
    Seymour, John Francis
    Gerecitano, John F.
    Kahl, Brad S.
    Pagel, John M.
    Wierda, William G.
    Anderson, Mary Ann
    Rudersdorf, Nikita
    Gressick, Lori A.
    Montalvo, Nicholas P.
    Yang, Jianning
    Zhu, Ming
    Dunbar, Martin
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod
    Roberts, Andrew Warwick
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Systematic Literature Review of the Clinical Evidence in Relapsed/Refractory (R/R) Large B-Cell Lymphoma
    Maloney, David G.
    Liu, Fei Fei
    Nientker, Lisette
    Alleman, Cathelijne
    Hutton, Brian
    Garcia, Jacob
    BLOOD, 2019, 134
  • [43] MYC plus relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy.
    Epperla, Narendranath
    Maddocks, Kami J.
    Salhab, Mohamed
    Chavez, Julio C.
    Reddy, Nishitha M.
    Karmali, Reem
    Umyarova, Elvira
    Bachanova, Veronika
    Glenn, Martha Jane
    Xavier, Ana Carolina
    Zhou, Zheng
    Hernandez-Ilizaliturri, Francisco J.
    Barta, Stefan K.
    Lansigan, Frederick
    Mehta, Amitkumar N.
    Flowers, Christopher
    Cohen, Jonathon Brett
    Fenske, Timothy S.
    Hamadani, Mehdi
    Costa, Luciano J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Long-term follow-up shows epcoritamab drives deep, durable responses in relapsed/refractory follicular lymphoma (R/R FL)
    Izutsu, K.
    Akahane, D.
    Toubai, T.
    Saito, T.
    Mishima, Y.
    Fujisaki, T.
    Kitawaki, T.
    Kumode, T.
    Suehiro, Y.
    Ishitsuka, K.
    Conlon, R.
    Noguchi, H.
    Buchbjerg, J.
    Favaro, E.
    Fukuhara, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1337 - S1337
  • [45] Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial
    de Vos, Sven
    Reagan, Patrick M.
    Patel, Manish R.
    Saba, Nakhle S.
    Mortlock, Andrew
    Cerec, Virginie
    Munugalavadla, Veerendra
    Acar, Melih
    Nuttall, Barrett
    Jenkins, David
    White, Rafael
    Callahan, Megan
    Forcina, Alessandra
    Roschewski, Mark
    Flinn, Ian W.
    BLOOD, 2022, 140 : 6635 - 6637
  • [46] Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States
    Saverno, Kimberly
    Nastoupil, Loretta
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Amoloja, Theresa
    Gentile, Danielle
    Asgarisabet, Parisa
    Epperla, Narendranath
    BLOOD, 2024, 144 : 2375 - 2376
  • [47] Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)
    Fowler, Nathan H.
    Trotman, Judith
    Auer, Rebecca
    Flowers, Christopher R.
    Reed, William F.
    Ivanova, Elena
    Huang, Jane
    Zinzani, Pier Luigi
    BLOOD, 2019, 134
  • [48] Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)
    Zhou, Lili
    Liu, Yifan
    Ye, Shiguang
    Li, Ping
    Li, Shaoguang
    Liang, Aibin
    BLOOD, 2023, 142
  • [49] Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
    Morschhauser, Franck
    Carlo-Stella, Carmelo
    Dickinson, Michael
    Phillips, Tycel
    Houot, Roch
    Offner, Fritz
    Haioun, Corinne
    Corradini, Paolo
    Hutchings, Martin
    Sureda, Anna
    Martinez-Lopez, Joaquin
    Wrobel, Tomasz
    Wu, Shang-Ju
    Lundberg, Linda
    Mulvihill, Estefania
    Perez-Callejo, David
    Relf, James
    Panchal, Anesh
    Humphrey, Kathryn
    Bachy, Emmanuel
    BLOOD, 2021, 138
  • [50] A Budget-Impact (BI) Analysis of Tazemetostat for the Treatment of 3L+Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States
    Watson, Lucy
    Harrison, Owen
    Cockrum, Paul
    Veazey, Kylee
    Gaugris, Sabine
    Kim, George
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S498 - S499
12345